Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression

Hormones and Cancer

Volumn 7, Issue 2, 2016, Pages 104-113

  Zhang, Ailin ^a   Zhang, Jiawei ^b   Plymate, Stephen ^c   Mostaghel, Elahe A ^a  

^a USA   (United States)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; 3 HYDROXYACYL COENZYME A DEHYDROGENASE; AKR1C2 PROTEIN, HUMAN; ANDROGEN RECEPTOR; AR PROTEIN, HUMAN; GLUCURONOSYLTRANSFERASE; HSD17B10 PROTEIN, HUMAN; HSD17B6 PROTEIN, HUMAN; HYDROXYSTEROID DEHYDROGENASE; ISOMERASE; MINOR HISTOCOMPATIBILITY ANTIGEN; UDP-GLUCURONOSYLTRANSFERASE 2B15, HUMAN; UGT2B17 PROTEIN, HUMAN;

CANCER GROWTH; CANCER RISK; DRUG METABOLISM; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; TUMOR XENOGRAFT; ANIMAL; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PROSTATE TUMOR;

3-HYDROXYACYL COA DEHYDROGENASES; ANIMALS; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MALE; MINOR HISTOCOMPATIBILITY ANTIGENS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RACEMASES AND EPIMERASES; RECEPTORS, ANDROGEN;

EID: 84955286241     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-016-0250-9     Document Type: Review

References (89)

1. Nelson PS et al (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 99:11890–11895
2. Nobel S, Abrahmsen L, Oppermann U (2001) Metabolic conversion as a pre-receptor control mechanism for lipophilic hormones. Eur J Biochem / FEBS 268:4113–4125
3. Penning TM, Bauman DR, Jin Y, Rizner TL (2007) Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor. Mol Cell Endocrinol 265–266:77–82. doi:10.1016/j.mce.2006.12.007
4. Mostaghel EA, Zhang A, Plymate S (2015) UDP-glucuronosyltransferase enzymes in prostate cancer progression: is only androgen catabolism involved? Eur Urol. doi:10.1016/j.eururo.2015.08.025
5. Mostaghel EA (2013) Steroid hormone synthetic pathways in prostate cancer. Trans Androl Urol 2:212–227. doi:10.3978/j.issn.2223-4683.2013.09.16
6. Rizner TL et al (2003) Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144:2922–2932. doi:10.1210/en.2002-0032
7. Rizner TL, Lin HK, Penning TM (2003) Role of human type 3 3alpha-hydroxysteroid dehydrogenase (AKR1C2) in androgen metabolism of prostate cancer cells. Chem Biol Interact 143–144:401–409
8. Ji Q, Chang L, VanDenBerg D, Stanczyk FZ, Stolz A (2003) Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 54:275–289
9. Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM (2006) Identification of the major oxidative 3{alpha}-hydroxysteroid dehydrogenase in human prostate that converts 5{alpha}-androstane-3{alpha},17{beta}-diol to 5{alpha}-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol 20:444–458
10. Mohler JL et al (2011) Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71:1486–1496. doi:10.1158/0008-5472.CAN-10-1343
11. Muthusamy S et al (2011) Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci U S A 108:20090–20094. doi:10.1073/pnas.1117772108
12. Huang XF, Luu-The V (2000) Molecular characterization of a first human 3(alpha-- > beta)-hydroxysteroid epimerase. J Biol Chem 275:29452–29457. doi:10.1074/jbc.M000562200
13. Hum DW et al (1999) Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 69:413–423
14. Guillemette C et al (1997) Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells. Endocrinology 138:2998–3005
15. Chouinard S, Barbier O, Belanger A (2007) UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem 282:33466–33474. doi:10.1074/jbc.M703370200
16. Chouinard S, Pelletier G, Belanger A, Barbier O (2004) Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocr Res 30:717–725
17. Turgeon D, Carrier JS, Levesque E, Hum DW, Belanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778–787
18. Valentini A et al (2007) Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Drug Metab Dispos Biol Fate Chem 35:968–972. doi:10.1124/dmd.107.014662
19. Levesque E et al (2001) Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 40:3869–3881
20. Koh E, Noda T, Kanaya J, Namiki M (2002) Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53:154–159
21. Lin HK et al (1997) Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol 11:1971–1984. doi:10.1210/mend.11.13.0026
22. Lin H-K, Steckelbroeck S, Fung K-M, Jones AN, Penning TM (2004) Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3[alpha]-hydroxysteroid dehydrogenase/type 5 17[beta]-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69:795–801
23. Fung KM et al (2006) Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 13:169–180
24. Jernberg E et al (2013) Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS One 8:e77407. doi:10.1371/journal.pone.0077407
25. Elo JP et al (1996) Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate. Int J Cancer 66:37–41
26. Ji Q et al (2007) Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 67:1361–1369
27. Stanbrough M et al (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815–2825
28. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB (2003) Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57:134–139
29. Montgomery RB et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447–4454. doi:10.1158/0008-5472.CAN-08-0249
30. Klein H, Bressel M, Kastendieck H, Voigt KD (1988) Androgens, adrenal androgen precursors, and their metabolism in untreated primary tumors and lymph node metastases of human prostatic cancer. Am J Clin Oncol 11(Suppl 2):S30–S36
31. Titus MA et al (2005) Steroid 5{alpha}-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11:4365–4371
32. Thomas LN et al (2007) Levels of 5[alpha]-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol In Press, Corrected Proof
33. Yun H, Xie J, Olumi AF, Ghosh R, Kumar AP (2015) Activation of AKR1C1/ERbeta induces apoptosis by downregulation of c-FLIP in prostate cancer cells: a prospective therapeutic opportunity. Oncotarget
34. Khvostova EP, Otpuschennikov AA, Pustylnyak VO, Gulyaeva LF (2015) Gene expression of androgen metabolising enzymes in benign and malignant prostatic tissues. Horm Metab Res 47:119–124. doi:10.1055/s-0034-1374631
35. He XY et al (2003) Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 87:191–198
36. Ishizaki F et al (2013) Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci Rep 3:1528. doi:10.1038/srep01528
37. Paquet S et al (2012) Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression. J Clin Endocrinol Metab 97:E428–E432. doi:10.1210/jc.2011-2064
38. Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K (2007) The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J Urol 178:1282–1288, discussion 1288–1289
39. Fankhauser M et al (2014) Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer. Clin Cancer Res 20:5547–5557. doi:10.1158/1078-0432.CCR-13-3483
40. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 17:657–664. doi:10.2119/molmed.2010.00143
41. Chang KH et al (2011) Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108:13728–13733. doi:10.1073/pnas.1107898108
42. Bennett NC et al (2012) Evidence for steroidogenic potential in human prostate cell lines and tissues. Am J Pathol 181:1078–1087. doi:10.1016/j.ajpath.2012.06.009
43. Jeong CW et al (2011) Limited expression of cytochrome p450 17alpha-hydroxylase/17,20-lyase in prostate cancer cell lines. Korean J Urol 52:494–497. doi:10.4111/kju.2011.52.7.494
44. Kumagai J et al (2013) Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. Prostate. doi:10.1002/pros.22655
45. Dillard PR, Lin MF, Khan SA (2008) Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol 295:115–120. doi:10.1016/j.mce.2008.08.013
46. Locke JA, Wasan KM, Nelson CC, Guns ES, Leon CG (2008) Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT). Prostate 68:20–33. doi:10.1002/pros.20674
47. Bao BY et al (2008) Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate 68:839–848. doi:10.1002/pros.20749
48. Grosse L et al (2013) Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications. Cancer Res 73:6963–6971. doi:10.1158/0008-5472.CAN-13-1462
49. Knuuttila M et al (2014) Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am J Pathol 184:2163–2173. doi:10.1016/j.ajpath.2014.04.010
50. Mostaghel EA et al (2014) Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis. PLoS One 9:e111545. doi:10.1371/journal.pone.0111545
51. Mostaghel EA et al (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913–5925. doi:10.1158/1078-0432.CCR-11-0728
52. Tenta R et al (2007) Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics 4:309–318
53. Belanger A et al (1998) Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol 65:301–310
54. Levesque E, Beaulieu M, Guillemette C, Hum DW, Belanger A (1998) Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 139:2375–2381
55. Kaeding J et al (2008) Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells. Mol Cancer Ther 7:380–390. doi:10.1158/1535-7163.MCT-07-0455
56. Agyeman AS et al (2012) Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat 132:175–187. doi:10.1007/s10549-011-1536-9
57. Amjad AI et al (2015) Broccoli-derived sulforaphane and chemoprevention of prostate cancer: from bench to bedside. Curr Pharmacol Rep 1:382–390. doi:10.1007/s40495-015-0034-x
58. Chang KH et al (2013) A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 154:1074–1084. doi:10.1016/j.cell.2013.07.029
59. Levesque E et al (2014) Importance of 5alpha-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer. Clin Cancer Res 20:576–584. doi:10.1158/1078-0432.CCR-13-1100
60. Sissung TM et al (2014) Genetic variation: effect on prostate cancer. Biochim Biophys Acta 1846:446–456. doi:10.1016/j.bbcan.2014.08.007
61. Sun T et al (2011) The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila) 4:2044–2050. doi:10.1158/1940-6207.CAPR-11-0283
62. Belledant A et al (2015) The UGT2B28 sex-steroid inactivation pathway is a regulator of steroidogenesis and modifies the risk of prostate cancer progression. Eur Urol. doi:10.1016/j.eururo.2015.06.054
63. Guillemette C, Levesque E, Harvey M, Bellemare J, Menard V (2010) UGT genomic diversity: beyond gene duplication. Drug Metab Rev 42:24–44. doi:10.3109/03602530903210682
64. Lampe JW, Bigler J, Bush AC, Potter JD (2000) Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y). Cancer Epidemiol Biomark Prev a Publ Am Assoc Cancer Res Am Soc Prev Oncol 9:329–333
65. Jakobsson J et al (2006) Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metabol 91:687–693. doi:10.1210/jc.2005-1643
66. Olsson M et al (2011) Correlation between circulatory, local prostatic, and intra-prostatic androgen levels. Prostate 71:909–914. doi:10.1002/pros.21307
67. Gauthier-Landry L, Belanger A, Barbier O (2015) Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution. J Steroid Biochem Mol Biol 145:187–192. doi:10.1016/j.jsbmb.2014.05.009
68. Gallagher CJ et al (2007) The UGT2B17 gene deletion polymorphism and risk of prostate cancer. A case–control study in Caucasians. Cancer Detect Prev 31:310–315. doi:10.1016/j.cdp.2007.07.005
69. Olsson M et al (2008) The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate 68:571–575. doi:10.1002/pros.20700
70. Setlur SR et al (2010) Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer. Cancer Epidemiol Biomark Prev: Publ Am Assoc Cancer Res Am Soc Prev Oncol 19:229–239. doi:10.1158/1055-9965.EPI-09-1018
71. Nadeau G et al (2011) Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab 96:E1550–E1557. doi:10.1210/jc.2011-1049
72. Park J et al (2006) Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomark Prev a Publ Am Assoc Cancer Res Am Soc Prev Oncol 15:1473–1478. doi:10.1158/1055-9965.EPI-06-0141
73. Park JY et al (2007) Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk. Urology 70:374–379. doi:10.1016/j.urology.2007.03.001
74. Karypidis AH, Olsson M, Andersson SO, Rane A, Ekstrom L (2008) Deletion polymorphism of the UGT2B17 gene is associated with increased risk for prostate cancer and correlated to gene expression in the prostate. Pharmacogenomics J 8:147–151. doi:10.1038/sj.tpj.6500449
75. Cai L, Huang W, Chou KC (2012) Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis. Protein Pept Lett 19:62–69
76. Kpoghomou MA, Soatiana JE, Kalembo FW, Bishwajit G, Sheng W (2013) UGT2B17 polymorphism and risk of prostate cancer: a meta-analysis. ISRN Oncol 2013:465916. doi:10.1155/2013/465916
77. Takahashi RH, Grigliatti TA, Reid RE, Riggs KW (2009) The effect of allelic variation in aldo-keto reductase 1C2 on the in vitro metabolism of dihydrotestosterone. J Pharmacol Exp Ther 329:1032–1039. doi:10.1124/jpet.109.150995
78. Jung KA et al (2013) Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Toxicol Lett 218:39–49. doi:10.1016/j.toxlet.2012.12.026
79. Burczynski ME, Sridhar GR, Palackal NT, Penning TM (2001) The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha, beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J Biol Chem 276:2890–2897. doi:10.1074/jbc.M006655200
80. Matsuura K et al (1998) Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem 124:940–946
81. Penning TM, Byrns MC (2009) Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci 1155:33–42. doi:10.1111/j.1749-6632.2009.03700.x
82. Huang KH et al (2010) Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology 57:384–394. doi:10.1111/j.1365-2559.2010.03647.x
83. Yepuru M et al (2013) Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res. doi:10.1158/1078-0432.CCR-13-1151
84. Fan L et al (2015) The steroidogenic enzyme AKR1C3 regulates stability of the ubiquitin ligase Siah2 in prostate cancer cells. J Biol Chem 290:20865–20879. doi:10.1074/jbc.M115.662155
85. Doig CL, Battaglia S, Khanim FL, Bunce CM, Campbell MJ (2016) Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. J Steroid Biochem Mol Biol 155:47–55. doi:10.1016/j.jsbmb.2015.09.037
86. Gruber M et al (2013) Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood 121:1175–1183. doi:10.1182/blood-2012-08-447359
87. Hirata H et al (2010) Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer. Carcinogenesis 31:1620–1626. doi:10.1093/carcin/bgq124
88. Liu C et al (2015) Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res 75:1413–1422. doi:10.1158/0008-5472.CAN-14-3080
89. Tamae D et al (2015) The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact 234:332–338. doi:10.1016/j.cbi.2014.12.012